Construction of multi-gene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers

Cancer Letters

Volumn 365, Issue 2, 2015, Pages 166-173

  Tsunashima, Ryo ^a   Naoi, Yasuto ^a   Kagara, Naofumi ^a   Shimoda, Masashi ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Shimazu, Kenzo ^a   Kim, Seung Jin ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemo sensitivity; ER positive breast cancer; Metabolic pathway; Neoadjuvant chemotherapy; Prognosis prediction

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LUTEINIZING HORMONE DERIVATIVE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DATA BASE; DECISION MAKING; DNA MICROARRAY; DNA PROBE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METABOLISM; MULTI GENE CLASSIFIER; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RESIDUAL CANCER BURDEN SCORE; SCORING SYSTEM; TRAINING; TREATMENT RESPONSE; TUMOR BIOPSY; VALIDATION STUDY; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; PROCEDURES; THEORETICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84937633341     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.030     Document Type: Article

References (40)

1. Esserman L.J., Berry D.A., DeMichele A., Carey L., Davis S.E., Buxton M., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J. Clin. Oncol 2012, 30:3242-3249.
2. Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., Blum R.H. Primary systemic therapy of breast cancer. Oncologist 2006, 11:574-589.
3. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
4. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med 2004, 351:2817-2826.
5. Ivshina A.V., George J., Senko O., Mow B., Putti T.C., Smeds J., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-10301.
6. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol 2009, 27:1160-1167.
7. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res. Treat 2011, 128:633-641.
8. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol 2006, 24:4236-4244.
9. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 2011, 117:3682-3690.
10. Sota Y., Naoi Y., Tsunashima R., Kagara N., Shimazu K., Maruyama N., et al. Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer. Ann. Oncol 2014, 25:100-106.
11. Sakamoto G., Inaji H., Akiyama F., Haga S., Hiraoka M., Inai K., et al. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005, 12(Suppl.):S1-S27.
12. Tsunashima R., Naoi Y., Kishi K., Baba Y., Shimomura A., Maruyama N., et al. Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy. Cancer Lett 2012, 324:42-47.
13. von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol 2012, 30:1796-1804.
14. Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110:244-254.
15. Alba E., Calvo L., Albanell J., De la Haba J.R., Arcusa Lanza A., Chacon J.I., et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann. Oncol 2012, 23:3069-3074.
16. Gong Y., Yan K., Lin F., Anderson K., Sotiriou C., Andre F., et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007, 8:203-211.
17. Gyorffy B., Benke Z., Lanczky A., Balazs B., Szallasi Z., Timar J., et al. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res. Treat 2012, 132:1025-1034.
18. Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011, 305:1873-1881.
19. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol 2007, 25:4414-4422.
20. Jiang Y., Yin W., Zhou L., Yan T., Zhou Q., Du Y., et al. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis. PLoS ONE 2012, 7:e32474.
21. Otani S., Masuda N. Abstract P3-12-03: adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Res 2013, 74.
22. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009, 69:4918-4925.
23. Martinez-Outschoorn U., Sotgia F., Lisanti M.P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol 2014, 41:195-216.
24. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005, 105:659-669.
25. Bayet-Robert M., Morvan D., Chollet P., Barthomeuf C. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res. Treat 2010, 120:613-626.
26. Schwarz-Dose J., Untch M., Tiling R., Sassen S., Mahner S., Kahlert S., et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J. Clin. Oncol 2009, 27:535-541.
27. Stahl A. A current review of fatty acid transport proteins (SLC27). Pflugers Arch 2004, 447:722-727.
28. Noetzel E., Rose M., Bornemann J., Gajewski M., Knuchel R., Dahl E. Nuclear transport receptor karyopherin-alpha2 promotes malignant breast cancer phenotypes in vitro. Oncogene 2012, 31:2101-2114.
29. Baron A., Migita T., Tang D., Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J. Cell. Biochem 2004, 91:47-53.
30. Migita T., Ruiz S., Fornari A., Fiorentino M., Priolo C., Zadra G., et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl Cancer Inst 2009, 101:519-532.
31. Hopperton K.E., Duncan R.E., Bazinet R.P., Archer M.C. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp. Cell Res 2014, 320:302-310.
32. Flavin R., Peluso S., Nguyen P.L., Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010, 6:551-562.
33. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
34. Wise D.R., Ward P.S., Shay J.E., Cross J.R., Gruber J.J., Sachdeva U.M., et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19611-19616.
35. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
36. Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J. Natl Cancer Inst 2005, 97:765-777.
37. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
38. Bozovic-Spasojevic I., Ameye L., Paesmans M., Larsimont D., Di Leo A., Dolci S., et al. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast 2014, 23:473-481.
39. Callagy G.M., Webber M.J., Pharoah P.D., Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
40. Miyoshi Y., Kurosumi M., Kurebayashi J., Matsuura N., Takahashi M., Tokunaga E., et al. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 2010, 17:103-109.